Zacks Analyst Blog Highlights: Qualcomm, Inc., Nokia, Johnson & Johnson, Cypress Bioscience, Inc. and Forest Laboratories, Inc.

CHICAGO--(BUSINESS WIRE)--Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Qualcomm, Inc. (NASDAQ: QCOM), Nokia (NYSE: NOK), Johnson & Johnson (NYSE: JNJ), Cypress Bioscience, Inc. (NASDAQ: CYPB) and Forest Laboratories, Inc. (NYSE: FRX).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579

Here are highlights from Monday’s Analyst Blog:

QCOM Our Biggest Telecom Buy

We maintain our Buy recommendation for Qualcomm, Inc. (NASDAQ: QCOM), the largest developer of digital mobile chipsets based on CDMA technology.

The company's fundamentals remain compelling since it has several industry-leading innovative products for a variety of wireless applications. Qualcomm's legal settlement with Nokia (NYSE: NOK) for royalty related issues and a new 15-year licensing agreement significantly strengthens business planning.

J&J Very Attractive

Johnson & Johnson (NYSE: JNJ) is one of the world's largest providers of healthcare products in the consumer, pharmaceutical and medical devices market. It has over 200 operating companies around the world and sells its products in more than 175 countries. J&J has an enormously diverse revenue stream consisting of market leading products in all three of its business segments.

Due to a number of products expected to experience declining sales, revenue growth in the next few years will likely slow relative to 2007. Incremental earnings growth will come in the form of improving margins and share buybacks. J&J's consistency, product diversity and financial stability make it a very attractive holding in this turbulent market.

Buy Cypress Bioscience

With a data from a third positive phase III trial in fibromyalgia released in early December 2008, we are feeling confident that the FDA will approve Cypress Bioscience, Inc.'s (NASDAQ: CYPB) and partner Forest Laboratories, Inc.’s (NYSE: FRX) milnacipran product during the first quarter of 2009.

Approval of milnacipran will be a transformational event for Cypress. The company should become almost immediately profitable based on royalties from Forest Labs. By 2013 we see total revenues exceeding $110 million, with net margins above 50%.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=2677

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4580.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.